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Abstract
Metabolic dysfunction, commonly a result of diets high in saturated fats and sugar, is associated with impaired cognitive
function and an increased risk of age-related cognitive decline (ACD) and Alzheimer’s disease (AD). Compared to the E3
isoform of apolipoprotein (apoE), the E4 isoform is a major genetic risk factor for ACD, AD, and for developing cognitive
impairments following various environmental challenges, including dietary challenges such as a high-fat diet (HFD). Both
insulin resistance (IR) and E4 are associated with metabolic and vascular impairments. Deficits in cerebral metabolism and
cerebrovascular function have been proposed as initiating events leading to these impairments. In the current study, we
employed a model of human apoE targeted replacement mice and HFD-induced obesity to study the potential link
between E4 and IR, at rest and following a postprandial challenge. HFD-induced IR was associated with impaired
cognition, reduced cerebral blood volume and decreased glucose uptake. These effects were more profound in E4
than E3 mice. Furthermore, the cognitive, metabolic and cerebrovascular responses to an exogenous glucose load
showed an apoE isoform-dependent response, with E4, but not E3 mice, acutely benefiting from a spike in blood glucose.
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Introduction
The elderly population is expanding rapidly, and by 2050,
the percentage of the world population aged 65 years or
older will more than double to 1.6 billion individuals.1
Concurrently, diabetes has reached epidemic proportions
worldwide.2 Projected rates of diabetes over the next two
decades are staggering; a 165% increase in the number of
patients with diabetes, with the largest increase in individuals over 75 years of age.3 Type 2 diabetes (T2D)
accounts for over 90% of all diabetes incidence and is
characterized by obesity and insulin resistance (IR).4
The major modiﬁable risk factor for T2D is obesity,
while the primary contributors to obesity are sedentary
lifestyle and caloric excess, particularly in the form of
‘‘Western’’ style diets high in saturated fat.5 Obesity,
IR, and T2D increase the risk of developing vascular
disease, including both atherosclerosis and vascular

dementia.4 Diabetes is also associated with an increased
incidence of Alzheimer’s Disease (AD),6–9 and it is
hypothesized that the two disorders are linked.10,11
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Apolipoprotein E (apoE) is associated with circulating lipoproteins, speciﬁcally very low-density lipoproteins (VLDL) and high-density lipoproteins (HDL).12
The APOE gene encodes for three isoforms in the
human population (E2, E3, and E4).12 Compared to
E3, E4 is associated with higher LDL cholesterol
levels and an increased risk of cardiovascular disease.13–14 E4 also dramatically increases the risk
for developing AD,15–17 and genome-wide association
studies conﬁrm that E4 is the strongest genetic risk
factor for AD.18,19
Cerebrovascular impairment has been proposed as
an initiating event leading to neuronal degeneration,20
and both IR and E4 have been linked to vascular
impairments. Individuals with T2D show lower resting
blood ﬂow in the brain and a reduced ability to maintain stable and suﬃcient cerebral blood ﬂow (CBF)
compared to controls.21,22 The microvasculature
within peripheral tissues is particularly sensitive to insulin, and this sensitivity is impaired by obesity and IR.23
Insulin has many important actions in the brain, and
brain IR has been proposed to contribute to the progression of AD.24 Furthermore, administration of
intranasal insulin results in enhanced cognition in
T2D patients that is related to regional vasoreactivity.22
Reduced CBF is seen in elderly E4 carriers relative to
non-carriers in multiple brain regions.25 Cognitively,
normal E4 individuals also show accelerated declines
in regional CBF during aging,26 and the association
between cognitive function and age-related changes in
CBF is modiﬁed by APOE genotype.27 In addition to
these diﬀerences in resting CBF, several studies have
shown diﬀerences in functional activation, as measured
by blood oxygen level dependent (BOLD), functional
magnetic resonance imaging (fMRI), in middle aged
and older E4 individuals.28 Importantly, E4-associated
alterations in brain physiology occur early in life and in
the absence of gross neuropathological changes and
preceding cognitive impairments.29 For instance, functional diﬀerences in CBF are present as early as the
second decade of life, with E4 carriers showing lower
or higher activation in diﬀerent regions of the temporal
gyrus during a nonverbal memory task relative to noncarriers.30
Cerebral metabolism is a primary determinant of
regional blood ﬂow, and because metabolic rate and
CBF are coupled, changes in brain metabolism are
likely to aﬀect CBF.31 AD is associated with a speciﬁc
pattern of regional glucose hypometabolism,32,33 and
glucose metabolism decreases during normal aging,
particularly aerobic glycolysis.34 Interestingly, a
consistent pattern of brain glucose hypometabolism –
similar to that seen in AD – has been noted in elderly
individuals with E4.35,36 Even cognitively normal E4
carriers demonstrate this pattern of glucose
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hypometabolism,37,38 and these metabolic deﬁcits
are present decades in advance of AD onset in E4
individuals.39
Despite the evidence linking IR and E4, very few
studies have focused on examining the potential neurobiological pathways that lie at the intersection of these
two critical risk factors. In the periphery, however,
there are established eﬀects of E4 on metabolism that
may indirectly aﬀect the brain.40 Recent studies suggest
that these peripheral metabolic eﬀects may aﬀect cognitive function in E4 individuals by inﬂuencing glucose
tolerance or modulating the response to a dietary challenge.41–43 In addition to the chronic eﬀects of glucose
dysregulation, as in IR, acute changes in glucose concentrations are also known to aﬀect cognitive function,
and these acute eﬀects can also be apoE isoform-dependent.43 Therefore, in the current study, we employed a
model of human apoE-targeted replacement mice and
HFD-induced obesity to study the potential link
between E4 and IR, at rest and following a postprandial challenge.

Methods
Experimental animals and diet
Female homozygous human E3- and E4-targeted
replacement mice44,45 were fed an HFD ad libitum
(60% kcal from fat, Research Diets D12492) or an ingredient-matched LFD (10% kcal from fat, D12450B)
beginning at 9 months of age. Prior to administration
of the HFD or LFD, mice consumed a standard chow
diet ad libitum (PicoLab Rodent Diet 20, #5053; PMI
Nutrition International, St. Louis, MO). All measures
were conducted following six months of specialized
diet (15 months of age). All procedures complied with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and with IACUC approval
at Oregon Health & Sciences University (OHSU), and
were in compliance with ARRIVE (Animal Research:
Reporting in Vivo Experiments) guidelines.

Metabolic and biochemical measurements
For the glucose tolerance test, mice were administered an
oral gavage of glucose solution (2 mg/g body weight).
For the insulin tolerance test, mice were intravenously
injected with 0.75 U/kg of human insulin (Gibco).
Blood glucose was measured using a glucometer
(One Touch Ultra) at indicated time points. For resting
glucose uptake, mice were injected following a 4-h
fast with 0.75 mCi of 2-[1,2-3H (N)]-deoxy-d-glucose
(Perkin Elmer) diluted in glucose solution (2 mg/d
body weight) via the tail vein. For glucose uptake
during the water maze test (see below), mice were
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administered an oral gavage (8 ml/g body weight) of
2-[1,2-3H (N)]-deoxy-d-glucose (0.06 mCi/g body
weight) diluted in glucose solution (2 mg/g body
weight) 14 min prior to a 1-min long memory trial (see
Cognitive Testing for details). Tissue glucose uptake was
adjusted to plasma values to adjust for variations in
injection volumes and dietary absorption. Fifteen
minutes after injection or gavage, mice were intraperitoneally administered a lethal dose of ketamine–xylazine–
acepromazine cocktail (0.01 ml/g of 25 mg/ml ketamine
(Sigma), 0.625 mg/ml acepromazine (Vetus Animal
Health), 3.125 mg/ml xylazine (Sigma)). To ﬂush out
remaining blood, mice were intracardially perfused
with 20 ml of 0.9% phosphate-buﬀered saline (PBS)
and tissue was collected. Approximately 100 mg of
tissue was homogenized in 4 ml of PBS. Brain and skeletal muscle homogenates were transferred to a scintillation vial, 1 ml of Optiphase scintillation ﬂuid (Perkin
Elmer) was added, and samples were measured on a
liquid scintillation counter (Beckman).

Cognitive testing
Spatial learning and memory were assessed using
the water maze test. The water maze consisted of a
circular pool (diameter 140 cm), ﬁlled with opaque
water (white chalk added, 24 C) divided conceptually
into four quadrants. Mice were given two sessions per
day (separated by three hours) consisting of two trials
each (separated by 5 min), over the course of ﬁve days
(two days ‘‘Visible Platform’’ followed by three days
‘‘Hidden Platform’’). Mice were ﬁrst trained to locate
an escape platform submerged below the surface of the
water, by the use of a cue during the ‘‘Visible Platform’’
trials. Mice were removed from the pool after locating
the platform and remaining on it for 3 s. Mice were
inserted in the maze at varying locations during each
trial to avoid procedural bias, and during the Visible
Platform trials, the location of the platform was moved
for each session between the four quadrants to avoid
procedural biases in task learning. Subsequent to the
‘‘Visible Platform’’ trials, mice were trained to locate
the platform hidden beneath opaque water during
the ‘‘Hidden Platform’’ trials, which required the mice
to rely on extra-maze cues for spatial reference and
orientation. Extra-maze cues consisted of four large
(50  50 cm) cues of diﬀerent shapes and color combinations, positioned at the borders of the four quadrants.
The platform was not rotated during the Hidden
Platform trials, remaining in the same location in the
‘‘Target’’ quadrant. Spatial memory retention was
assessed 72 h following the ﬁnal ‘‘Hidden Platform’’
training session. The submerged platform was removed
and spatial memory retention assessed during these
‘‘Probe’’ trials by calculating the cumulative distance
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to the target and the time spent searching in each quadrant. For assessing eﬀects of acute glucose supplementation on cognitive function, mice were given an oral
gavage of glucose solution (2 mg/g body weight) 15 min
prior to testing during the 72 h probe trial.

Cerebral blood volume measurement
To measure vascular perfusion (volume of bloodperfused vessels, referred to as cerebral blood volume
(CBV)) in vivo, we employed optical microangiography
(OMAG), as previously described.46,47 Brieﬂy, mice
were anesthetized with ketamine (50 mg/kg) and body
temperature was maintained at 37  0.5 C using a
warm water pad. The skin over the skull was reﬂected,
the cortex illuminated through the intact skull at
1310 nm, and the resulting backscattered and reference
light detected to produce spectral interferograms. CBV
was measured in three branch areas of the middle cerebral artery (MCA) at positions centered approximately
0.0 to 1.0 mm caudal to bregma, and 1.0 to 2.0 mm
lateral from the midline suture through the skull. For
measures of the eﬀects of glucose supplementation on
CBV, the third area was measured at 0 min, and again
at 15 min, post intravenous injection of 250 ml of a
0.25 mg/ml glucose solution. Vessel diameters were measured for each branching segment of the MCA within
the 1 mm3 scan area, and pixel intensity histograms were
generated using Amira software (FEI) at the Multiscale
Microscopy Core (MMC) with technical support from
the OHSU-FEI Living Lab and the OHSU Center for
Spatial Systems Biomedicine (OCSSB).

Statistical analyses
Data are expressed as mean  standard error. Multiple
groups and/or multiple time points were analyzed using
analysis of variance (ANOVA) (groups ¼ E3 LFD, E4
LFD, E3 HFD, E4 HFD) using Graph Pad Prism software (San Diego, CA), or repeated measures ANOVA
(time  groups) using SPSS software (Chicago, IL).
Statistically signiﬁcant correlations were determined
using an error probability level of p < 0.05 corrected
by a false discovery rate (FDR) analysis (Benjamini
Hochberg method).

Results
E4 HFD mice gain less weight than E3 HFD mice but
show similar degree of IR
While HFD led to increased body weight and adipose
tissue in both E3 and E4 mice, E4 HFD mice gained
less weight and less adipose tissue than E3 HFD mice
(Figure 1(a) and (b)). HFD also led to elevated fasting
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Figure 1. E4 HFD mice gain less weight than E3 HFD mice but show similar degree of insulin resistance. (a) E4 mice gain less weight
when fed an HFD than E3 mice fed an HFD. n ¼ 5–9. (b) E4 HFD mice accumulate less visceral adipose tissue than E3 HFD mice
following six months of HFD (n ¼ 5–9). (c) HFD leads to hyperglycemia in E3 and E4 mice. Blood glucose was measured following a 4-h
fast. n ¼ 20–26. (d) Glucose intolerance is exaggerated in HFD mice. Mice were administered an oral gavage of glucose following a 4hour fast. n ¼ 11–14. (e) Insulin sensitivity is diminished in HFD mice. Insulin was injected following a 4-h fast and blood glucose was
measured. n ¼ 9–10. (a, d–e, ** p < 0.01, E3 vs. E4; # p < 0.05, ## p < 0.01, HFD vs. LFD; repeated measures ANOVA) (b–c, **
p < 0.01, E3 vs. E4; # p < 0.05, ## p < 0.01, HFD vs. LFD; two-way ANOVA followed by t-test).

plasma glucose concentrations and deﬁcits in glucose
tolerance and insulin sensitivity, with a similar degree
of impairment observed in E3 and E4 HFD mice
(Figure 1(c) to (e)). LFD-fed E3 and E4 mice did not
diﬀer in any of the measured markers of peripheral
metabolism (Figure 1(a) to (e)).

with E4 HFD mice showing the lowest CBV within
vessels of these diameters (Figure 2(d)). The changes
in CBV appear unrelated to diﬀerences in vessel morphology, with all groups showing a similar number of
blood vessels, total vessel length, and degree of branching (Suppl Figure 1(a) to (c)).

E4 and HFD reduce CBV

A bolus of glucose improves spatial memory in E4
HFD mice

A potential physiological link between HFD-induced
and E4-associated cognitive dysfunction is the regulation of CBF. To determine whether the observed cognitive impairments are associated with alterations
in cerebrovascular function, we quantiﬁed CBV, a
measure of vascular perfusion. Using OMAG, we measured CBV within pial vessel branches of the MCA
(Figure 2(a) and (b)). Total CBV showed a signiﬁcant
eﬀect of diet and genotype (p ¼ 0.002 and p ¼ 0.026,
respectively, two-way ANOVA), with E4 HFD mice
having the lowest rates of CBV (Figure 2(c)). HFD
mice showed lower CBV in microvessels (<10 mM
diameter) and small-sized vessels (20–40 mM diameter),

Previous studies demonstrated measurable changes in
cognitive performance following acute meal interventions, including a variable response to low versus high
glycemic index (GI) meals.48 Recent work suggests that
these acute dietary eﬀects are modulated by apoE isoform, with E4þ, but not E4, individuals displaying
cognitive gains immediately following a high GI
meal.43 Therefore, we next asked whether E4 mice
would similarly beneﬁt more than E3 mice from a postprandial spike in pure glucose (GI ¼ 100; standard
value). To assess cognitive function, we measured spatial
memory retention in the water maze. Fifteen minutes
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Additionally, when compared to their saline-treated
counterparts, E3 mice receiving a glucose gavage
prior to the memory probe searched further from
the target location over the course of the memory
probe trial, while E4 mice receiving a glucose gavage
searched substantially closer to the platform location
(Figure 3(c)). Together, these data demonstrate that a
bolus of glucose diﬀerentially aﬀects acute cognitive
performance based on APOE genotype, with E3 mice
suﬀering, and E4 mice beneﬁtting, from a spike in dietary glucose.

A bolus of glucose increases CBV in E4 HFD mice

Figure 2. E4 and HFD reduce cerebral blood volume, a measure of vascular perfusion. (a–b) Diagram of vascular beds imaged
and representative image of cerebral blood volume (CBV) and
measures of vessel diameter. CBV was measured within pial
vessel branches of the middle cerebral artery (MCA) using
optical microangiography. CBV was measured within three distinct 1 mm3 scan regions (boxed areas, 1–3) for each mouse, and
vessel diameter determined and CBV was quantified. (c) Total
CBV (each mouse ¼ average of three scans). n ¼ 7–8. (d)
Histogram of CBV across small vessels of varying diameters.
*p < 0.05, E3 vs. E4; #p < 0.05, HFD vs. LFD; two-way ANOVA
followed by t-test.

prior to a 72-h memory probe trial, mice were given a
gavage of either glucose or saline. In saline-gavaged
HFD mice, spatial memory retention was impaired in
both E3 and E4 mice, as shown by a lack of spatial bias
and a lack of spending more time in the target quadrant
than any other quadrant (Figure 3(a), open bars).
However, in HFD mice orally administered glucose
prior to the memory probe, the cognitive eﬀects diﬀered
depending on APOE genotype despite similar increases
in blood glucose concentrations (Suppl Figure 2(a)).
Compared to E3 LFD mice given a gavage of saline,
E3 LFD mice given a gavage of glucose showed signiﬁcant impairments in spatial memory retention, as measured by time spent searching in the target quadrant
(Figure 3(a)) and cumulative distance from the target
(Figure 3(b)). Conversely, E4 HFD mice showed signiﬁcant improvement in spatial memory retention following an oral gavage of glucose (Figure 3(a) and (b)).

To determine whether the postprandial changes in
spatial memory retention were associated with cerebrovascular function, we measured CBV in E3 and E4 mice
before and 15 min after an injection of a glucose solution (Figure 4(a)). While all groups showed similar
increases in blood glucose concentrations following
injection (Suppl Figure 2(b)), only E4 HFD mice
demonstrated a signiﬁcant CBV response to the acute
hyperglycemia. There was a signiﬁcant genotype eﬀect
on post-glucose CBV (p ¼ 0.028, ANOVA) and a trend
towards genotype  diet interaction (p ¼ 0.0526, twoway ANOVA), with E4 mice showing larger increases.
Total CBV was signiﬁcantly increased in E4 HFD
mice compared to E3 HFD mice (p ¼ 0.018, t-test)
(Figure 4(b)), and these increases were observed
across small vessels of varying diameters (Figure 4(c)).

E4 and HFD decrease brain glucose uptake at rest
and during a memory task
We next asked whether the cognitive beneﬁts observed
in E4 HFD mice following a bolus of glucose were
associated with an increase in tissue glucose uptake.
To answer this, mice were administered radiolabeled
2-deoxyglucose (2DG) at rest, or prior to a memory
test, and glucose uptake in the two primary organs
expected to be activated during the water maze –
brain and skeletal muscle – was assessed. While there
was no signiﬁcant eﬀect of APOE or diet on resting
glucose uptake in skeletal muscle, E4 was associated
with reduced brain glucose uptake at rest (p ¼ 0.0274,
two-way ANOVA) (Figure 5(a) and (b)). To determine
glucose uptake during a cognitive challenge, mice were
given an oral gavage of 3H-2DG 14 min prior to a water
maze probe and tissue uptake was assessed immediately
following the 1-min long memory test. Glucose uptake
during the cognitive challenge was signiﬁcantly reduced
by both E4 and HFD in brain and skeletal muscle
(APOE, p ¼ 0.0466 brain, p < 0.01 muscle; Diet
p < 0.01, both tissues; two-way ANOVA) (Figure 5(c)
and (d)). Together, these data show that E4 and HFD
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Figure 3. A bolus of glucose improves spatial memory in E4 HFD mice. (a) A glucose gavage differentially affects acute cognitive
performance based on APOE genotype. Spatial memory retention was measured as the percent time spent searching in the target
quadrant a 72-h probe trial. (Quadrants: T: target; R: right; L: left; O: opposite). n ¼ 7–13. (* p < 0.05, ** p < 0.01, Target compared to
all other targets, ANOVA followed by t-tests). (b) E3 LFD mice show impaired memory retention in the water maze following a
glucose gavage, while E4 HFD shows improved memory retention. Spatial memory was analyzed by calculating the cumulative distance
to the target, a measure of search accuracy during the 72-h memory probe trial. n ¼ 7–13. (* p < 0.05, t-test). (c) Change in cumulative
distance to the target platform location compared to genotype- and diet-matched mice gavaged with saline. The mean change in
cumulative distance was calculated for each group (mean of the glucose gavage group minus the mean of the saline gavage group).
Compared to saline-treated E3 mice, E3 LFD and E3 HFD mice receiving a glucose gavage prior to the memory probe searched
further from the target location over the course of the memory probe trial, suggesting a relative impairment in spatial memory.
Conversely, E4 LFD and E4 HFD mice receiving a glucose gavage searched closer to the target location, suggesting a relative
improvement in spatial memory. (* p < 0.05 compared to all other targets, ANOVA).

are associated with lower brain glucose uptake, and that
these eﬀects are magniﬁed during a cognitive challenge.

Discussion
Increasing evidence suggests that cognitive impairments
as a result of both IR and E4 share common
pathological features and involve similar changes in
metabolism and cerebrovascular function. For
instance, there is overlap between the cerebrovascular
pathologies observed in diabetic patients and in individuals with E4,49 and both IR and possession of E4
have been independently associated with ineﬃcient
brain glucose hypometabolism and reduced cerebral
blood ﬂow.25–27,50,51 Furthermore, these two factors
may interact to impair cognition and promote neurodegeneration.7,52–54 In the current study, we further
examined this potential interaction, and whether the
eﬀects are mediated via cerebrovascular function and
can be modiﬁed by changes in postprandial glucose.

Here, we show that both E4 and HFD-induced IR
reduce CBV and glucose uptake, primarily in an additive fashion. However, the cognitive, metabolic and
cerebrovascular responses to an exogenous glucose
load varied considerably depending on APOE genotype, with E4, but not E3 mice, acutely beneﬁting
from a spike in blood glucose.
ACD and AD share several key risk factors with
cerebrovascular disease, such as hypertension, cerebral
hypoperfusion, diabetes, hypercholesterolemia, and E4
carriage.55 Establishing the role of cerebrovascular dysfunction in ACD and AD has become even more
important following recent studies that suggest a
majority of clinically diagnosed AD is mixed pathology
or vascular disease.56 APOE genotype itself has clear
eﬀects on several risk factors for dementia noted above,
such as obesity,57–61 hypercholesterolemia,13,14 and peripheral vascular disease.62–64 Increasing in vivo and
in vitro evidence also points to multiple cerebrovascular
eﬀects of APOE in the brain.65–70
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Figure 4. A bolus of glucose increases CBV in E4 HFD mice.
(a) CBV was measured in E3 and E4 mice using OMAG at 0 and
15 min after an injection of a glucose solution. (b–c) Glucose
increases CBV in E4 HFD mice. (b) Percent increase in total
CBV following the glucose injection. (c) CBV at 0 and 15 min
post-glucose injection across small vessels of varying diameters.
n ¼ 6–7. (* p < 0.05, two-way ANOVA followed by t-test).

Cerebral blood ﬂow (CBF) is decreased in ACD and
in AD patients.71,72 However, it remains unclear
whether cerebral hypoperfusion drives the neurodegenerative process, or whether these deﬁcits simply reﬂect
diminished demand as a result of aging and/or neurodegeneration. In the case of E4, both lower25,26,30 and
higher27,73 CBF have been observed in individuals with
E4, with results diﬀering depending on the age of the
carriers.25 Still, some research suggests that hypoperfusion precedes, and possibly contributes to, the onset of
dementia,74 and in fact decreased resting CBF is
observed in E4þ individuals as young as their early
twenties.30 Given that cognitive function relies on an
eﬃcient and responsive vascular system, it has been
further speculated that the accelerated ACD and AD
pathogenesis associated with E4 may result from its
harmful eﬀects on the cerebrovasculature.75
In the current study, we assessed CBV, a measure of
vascular perfusion, using OMAG, which allows for
in vivo, 3D, volumetric quantiﬁcation of bloodperfused vessels with capillary resolution.47 While historically CBF was believed to be regulated strictly at
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Figure 5. E4 and HFD decrease brain glucose uptake at rest
and during a cognitive task. (a–b) Resting glucose uptake in brain
(a) and skeletal muscle (b). Following a 4-h fast, tissue uptake of
3
H-2-deoxyglucose was measured 15 min following an i.v. injection of glucose solution. n ¼ 13–19. (c–d) Glucose uptake in brain
(c) and skeletal muscle (d) during a cognitive challenge. Following
a 4-h fast, mice were administered an oral gavage of glucose
solution containing 3H-2-deoxyglucose and 14 min later were
subjected to a 1-min long water maze memory probe. n ¼ 4–9.
(*p < 0.05, ^p ¼ 0.06, E3 vs. E4; ## p < 0.01, HFD vs. LFD; twoway ANOVA followed by t-test).

the level of penetrating arterioles, it has recently been
shown that capillaries are ﬁrst to respond via neuronpericyte signaling,76 and results suggest that human
imaging studies relying on BOLD may largely reﬂect
capillary function.77 Our group also recently highlighted the importance of cerebral microvessel function
in vivo, linking microvascular perfusion and cognitive
performance in a mouse model of diet-induced obesity
and IR.46 Similarly, in the current study, we observed a
signiﬁcant decrease in CBV in HFD fed mice. Here, we
also observed a signiﬁcant decrease in CBV in E4, compared to E3 mice, in the absence of overt changes in
vessel morphology. These results are contrary to that
observed by Bell et al.65 showing E4-associated reductions in microvascular length. This discrepancy could
be due to experimental methods; using OMAG, we can
only visualize vessels with an active ﬂow component
(i.e. moving red blood cells (RBCs)), and therefore
non-patent vessels would not be visualized and counted
using our methodology. Future experiments aimed at
carefully detailing potential structural diﬀerences in an
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apoE model – across age and according to diet or metabolic status – would be valuable. Finally, E4 HFD mice
were the only group to show a CBV response to an
acute increase in blood glucose. This group was also
the only group to signiﬁcantly improve in cognitive performance following a bolus of glucose. However, glucose uptake during the cognitive challenge in E4 HFD
mice remained signiﬁcantly lower than E3 HFD or
LFD mice, which may speak to a potential uncoupling
of CBF and glucose uptake. Perhaps the increase in
CBV in E4 HFD mice following a glucose gavage,
in the absence of increased glucose uptake, reﬂects an
inability of E4 cells to take up glucose in the face of
pro-uptake signaling. In other words, perhaps neural
activity is able to stimulate CBV in E4 mice, but a
dearth of glucose transporter expression or impaired
function limits glucose uptake. The exact mechanism
behind this potential apoE-speciﬁc glucose uptake and
CBF uncoupling, however, remains unknown, and warrants future studies.
Evidence from other in vivo studies also highlights
CBF as a potential link between E4 and impaired
cognition. For example, using a ﬂow-sensitive MRI
technique, Wiesmann et al.70 recently showed that
18-month-old E4 mice had reduced CBF compared to
WT mice. Similarly, Lin et al.68 showed that E4 mice
have reduced CBF compared to WT mice using MRI.
Furthermore, they showed CBF improvements in E4
mice following treatment with rapamycin, a pleiotropic
compound with various metabolic eﬀects, and provided
evidence that the blood–brain barrier (BBB) is involved
in mediating the eﬀects of E4 on CBF.68 BBB dysfunction can lead to microvascular impairments, and thus
represents a plausible neurovascular pathway leading
to neurodegeneration and AD.78 Interestingly, APOE
genotype has recently been associated with BBB function in multiple studies, with E4 leading to increased
BBB permeability, reductions in cerebral vascularization, thinner vessel walls and reduced CBF.65,66
Importantly, vascular defects have been observed as
early as two weeks of age in E4 mice,65 well preceding
the neuronal and synaptic dysfunction that is observed
in these mice at later ages. These early-life BBB defects
highlight an important variable between studies,
namely the age at which the measurements were conducted. Age is an important contributor to cerebral
metabolic and vascular function, and APOE may
modify these age-related changes.27,34,71 For instance,
changes in the relationship between cognitive function
and CBF during normal aging are modiﬁed by APOE
genotype.27 While our own study demonstrated
E4-associated cerebrovascular deﬁcits at 15 months of
age, Bell et al.65showed reduced CBF in E4 mice at 9
months of age, Wiesmann et al.70 at 18-months of age,
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and Lin et al.68 at 1, 2, 4 and 7 months of age. While the
various imaging modalities employed makes comparisons diﬃcult, taken together, these studies show that
E4-associated reductions in CBF are present across the
lifespan in mice. Finally, reductions in microvascular
length and decreased brain capillary density have been
reported in several animal models of AD,79–81 again
stressing the overlap of AD and cerebrovascular disease
risk factors such as E4 and IR.
While possession of E4 is a clear genetic risk factor
for AD, environmental inﬂuences also contribute to
disease risk and progression. In particular, ‘Western
style diets’, high in saturated fats and high GI foods,
show a consistent association with increased AD pathology.82–86 Rodent studies also support the idea that
high saturated fat diets and high GI diets lead to cognitive dysfunction, insulin dysregulation, increase
inﬂammation, and exacerbate levels and accumulation
of the hallmark neurotoxic AD protein amyloid-b
(Ab).53,87–89 Additionally, APOE genotype appears to
modify the eﬀects of diet on AD risk, as well as the
response to various diet interventions.90 For instance,
epidemiological studies generally suggest that diets high
in saturated fat and simple sugars increase the risk of
AD, but less so in individuals with E4,91–94 while intervention trials involving ketogenic diets and omega-3
fatty acid supplementation show muted beneﬁts in
E4þ participants.48,83,95 This gene-diet interaction is
seen in mice as well, with diet-induced obesity diﬀerentially aﬀecting E4 and E3 mice in terms of tau phosphorylation,96 as well as glial activation and amyloid
deposition.97 Additionally, a recent study by our group
showed that compared to mice with E3, mice expressing
E4 are particularly sensitive to HFD-associated cognitive impairments.53 In addition to an exacerbation of
cognitive impairment in E4 mice fed a HFD, we also
highlighted multiple changes in metabolic pathways
either directly or indirectly tied to glucose metabolism.53
Finally, diet-induced IR may induce a bioenergetic shift
away from glucose as the primary cerebral fuel source to
alternative sources of energy such as fatty acids 98,99 – a
bioenergetic shift that we and others recently suggested
may be an inherent feature of E4.58,60
Despite the epidemiological evidence suggesting that
APOE genotype modiﬁes the eﬀects of diet on AD risk,
long-term diet interventions are challenging to conduct
and interpret. Therefore, studies designed to examine
acute cerebral responses to speciﬁc diets and/or supplements may provide a clearer path to identifying the
mechanisms which underlie APOE-diet interactions.
Acute, single meal interventions are able to produce
measurable cognitive eﬀects,48 and while the results
are oftentimes equivocal, the eﬀects of acute hyperglycemia on mood and cognition have been relatively well
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studied. In elderly subjects, the majority of studies show
improvements in episodic memory following a glucose
load, while other cognitive domains such as working
memory, semantic memory and visual memory, showing less frequent evidence.100 The eﬀects of acute hyperglycemia in people with IR or diabetes are likewise
ambiguous, with both detrimental and beneﬁcial eﬀects
on mood and cognition being reported.101
Hanson et al.43 recently took an acute dietary
approach in a clinical research study in which subjects
with varying APOE genotype were administered acute
dietary challenges, and their metabolic and cognitive
responses measured. Interestingly, cognitively normal
subjects carrying E4 showed higher memory scores following a meal with a high GI and high in saturated fat
(HIGH meal), while subjects who did not have E4 had
lower memory scores as compared to genotypematched controls.43 Additionally, cognitively impaired
individuals with E4 had enhanced executive function
following the HIGH meal, while cognitively normal
E4-subjects showed reduced executive function.43
Similarly, we report here that mice expressing E4, but
not those with E3, showed improvements in cognitive
performance, as well as increases in CBV, following
acute administration of a high GI load (glucose,
GI ¼ 100). Taken together, our studies suggest that a
spike in blood glucose from a high GI meal is acutely
beneﬁcial for cognitive performance in E4þ, but not
E4-, individuals, and that the observed improvements
may be mediated by increased cerebral blood ﬂow.
Increased eﬀorts are warranted to assess the eﬀect of
IR in E4 carriers, particularly mechanistic studies to
clarify the relationship between APOE genotype, cerebral glucose metabolism, CBF, and their interactive
eﬀects on cognitive function.
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